Hengrui Pharma's five subsidiaries have been approved to conduct clinical trials for drugs
Hengrui Pharma (01276.HK) announced that five subsidiaries received approval from the National Medical Products Administration for the issuance of the "Drug Clinical Trial Approval Notice," including: Shanghai Hengrui for the clinical trial of injectable leuprolide acetate microspheres for prostate cancer; Suzhou Shengdi and Shanghai Hengrui for the clinical trials of SHR-9539 injection and HRS-3738 tablets; Beijing Shengdi for the clinical trial of SHR-2906 injection for overweight or obesity; and Shanghai Hengrui, Shandong Shengdi, and Chengdu Shengdi for the clinical trials of HRS-6208 capsules, HRS-6209 capsules, HRS-8080, and HRS-1358 tablets, and HRS-5041
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments